Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
Nabriva Therapeutics plc (OTC : NBRVF) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
Quote
| Last: | $0.0001 |
|---|---|
| Change Percent: | 0.0% |
| Open: | $0.0001 |
| Close: | $0.0001 |
| High: | $0.0001 |
| Low: | $0.0001 |
| Volume: | 361 |
| Last Trade Date Time: | 06/01/2026 10:09:41 am |
Stock Data
| Market Cap: | $646 |
|---|---|
| Float: | 3,198,529 |
| Insiders Ownership: | 0.82% |
| Institutions: | 13 |
| Short Percent: | 44595% |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.nabriva.com |
| Country: | IE |
| City: | Dublin |
Recent News Releases
Subscribe to Our Newsletter
**MWN-AI FAQ is based on asking OpenAI questions about Nabriva Therapeutics plc (OTC: NBRVF).
